Artificial intelligence is increasingly becoming a cornerstone in drug discovery, and VERAXA Biotech AG (NASDAQ: VRXA) is looking to harness its potential to strengthen its oncology pipeline. The company was recently featured in an article highlighting its collaboration with Ardigen, an AI-focused research organization, to combine computational biology and bioinformatics with VERAXA’s proprietary BiTAC(R) platform.
The partnership is designed to use AI to identify optimal dual-target combinations for T-cell engagers and antibody-drug conjugates (ADCs), while also improving target validation and reducing development risks. VERAXA’s approach, which the company describes as “AND-gated,” activates therapies only when two cancer-associated targets are present on the same cell. This specificity may be particularly well suited to AI-driven analysis of complex genomic, proteomic, and clinical datasets.
According to the article, the technology could also enable researchers to revisit historical clinical and preclinical data, potentially identifying safer applications for targets or therapies that were previously abandoned because of toxicity concerns. This aspect of the collaboration could breathe new life into drug candidates that had been shelved, offering a pathway to repurpose them with a more favorable safety profile.
VERAXA is focused on building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T-cell engagers, bispecific ADCs, and other innovative formats. The company’s pipeline is guided by rigorous quality-by-design principles, and it is advancing its proprietary BiTAC formats into clinical development. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research.
The implications of this collaboration are significant. By integrating AI into the drug development process, VERAXA could accelerate the identification of promising drug candidates, reduce the time and cost associated with traditional trial-and-error methods, and increase the likelihood of clinical success. The ability to analyze large datasets and uncover patterns that might not be apparent to human researchers could lead to more precise targeting of cancer cells, potentially improving patient outcomes and reducing side effects.
Moreover, the collaboration underscores a broader trend in the pharmaceutical industry, where AI is being used to enhance various stages of drug development, from target identification to clinical trial design. Companies that successfully leverage AI may gain a competitive edge, bringing innovative therapies to market faster and more efficiently.
For those interested in the full article, it can be accessed at https://ibn.fm/2U2hQ. Additional news and updates about VERAXA Biotech are available in the company’s newsroom at https://ibn.fm/VRXA.
